Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.47 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20428076 | 1.00 | LMNA (0.52) | LMNASCN2ASCN10AMAPK1SLC13A5 | |
| SCHEMBL12675417 | 0.88 | KCNA5 (0.46) | LMNAMAPK1SLC13A5NAMPTKCNA5 | |
| SCHEMBL16829010 | 0.83 | NAMPT (0.45) | LMNANAMPTKCNA5KDM4AL3MBTL1 | |
| SCHEMBL15804093 | 0.82 | NAMPT (0.46) | LMNANAMPTKCNA5KDM4AL3MBTL1 | |
| SCHEMBL12578946 | 0.82 | ATR (0.47) | LMNASCN2ASCN10AMAPK1NAMPT | |
| SCHEMBL35210561 | 0.81 | NAMPT (0.46) | LMNANAMPTKCNA5KDM4AL3MBTL1 | |
| SCHEMBL17018589 | 0.81 | NAMPT (0.46) | LMNANAMPTKCNA5KDM4AL3MBTL1 | |
| SCHEMBL31098519 | 0.81 | BRD4 (0.50) | LMNANAMPTKCNA5KDM4AL3MBTL1 | |
| SCHEMBL8214960 | 0.81 | AKT1 (0.52) | LMNAHPGDNAMPTSMN1; SMN2KMT2A | |
| SCHEMBL31036966 | 0.81 | LMNA (0.56) | LMNASCN2ASCN10AMAPK1SLC13A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | H. LUNDBECK A/S (DK) | 2023-12-26 | — | — | US | disclosed |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | H. LUNDBECK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-11-08 | — | — | US | disclosed |
| EP-3728274-B1 | MACROCYCLES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | PDE3B, PDE1B, PDE12 | LMNA 2745/4885SCN2A 2159/4885SCN10A 1410/4885 |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | LMNA 2982/4885SCN2A 2238/4885SCN10A 1460/4885 |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | PDE1B, PDE3B, PDE1A | LMNA 3970/4885SCN2A 2076/4885SCN10A 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.